Novel oral anticoagulants in the management of polycythemia vera and essential thrombocythemia.

Polycythemia vera and essential thrombocythemia comprise myeloproliferative neoplasms, the main characteristic of which is an over-production of bone marrow myeloid lineage cells. The diseases typically involve thrombosis and their treatment, apart from the strictly hematological aspect, involves antithrombotic agents. In this review we aspire to present the possible role of the newly developed oral anticoagulants in the treatment scheme of polycythemia vera and essential thrombocythemia.